A clinical trial update dated August 6, 2026 lists goserelin in connection with a study evaluating imlunestrant (LY3484356) in premenopausal women with estrogen receptor-positive, HER2-negative early breast cancer. The trial, registered as NCT07287098, is titled "A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast Cancer." The study is currently listed as Phase 2. Its status is recruiting as of the update date. No outcome data or results have been posted for this trial at this stage. The listing does not specify additional details beyond the phase, status, and title provided. Readers should note that recruiting status means the trial is actively enrolling participants but has not yet reported findings. Further information about eligibility, trial design, or endpoints is available through the official registry listing. This update reflects only the current recruitment status as recorded on the specified date. No efficacy or safety conclusions can be drawn from this status update alone. For more background on goserelin as a compound, readers can consult the compound overview.
Goserelin Featured in Phase 2 Imlunestrant Trial for ER+ HER2- Breast Cancer
Drafted by an automated content engine from FDA, PubChem, ClinicalTrials.gov, NIH DSLD, and Open Beauty Facts data.
See the full goserelin overview
Source: https://clinicaltrials.gov/study/NCT07287098